Advertisement
The Board of Directors today also declared a quarterly dividend of $3.75per share on the 2007 Mandatory Convertible Preferred Stock. Payment will bemade on Feb. 15, 2008, to holders of record at the close of business on Feb.1, 2008. As of Sept. 30, 2007, there were 10,000,000 shares of 2007 MandatoryConvertible Preferred Stock outstanding.
Advertisement
Schering-Plough is an innovation-driven, science-centered global healthcare company. Through its own biopharmaceutical research and collaborationswith partners, Schering-Plough creates therapies that help save and improvelives around the world. The company applies its research-and-developmentplatform to human prescription and consumer products as well as to animalhealth products. In November 2007, Schering-Plough acquired OrganonBioSciences, with its Organon human health and Intervet animal healthbusinesses, marking a pivotal step in the company's ongoing transformation.Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors,patients, customers and other stakeholders served by its approximately 50,000people around the world. The company is based in Kenilworth, N.J., and itsWeb site is www.schering-plough.com.
SOURCE Schering-Plough Corporation
